Recent developments in the biology and therapy of T-cell and natural killer-cell lymphomas

被引:16
|
作者
Porcu, P
Baiocchi, RA
Magro, C
机构
[1] Ohio State Univ, Dept Med, Div Hematol Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Pathol, Div Dermatopathol, Columbus, OH 43210 USA
关键词
T/NK-cell lymphoma; mouse model; oncogenes; chromatin remodeling; cytokines; retinoids; campath-1; H; monoclonal antibodies; NON-HODGKINS-LYMPHOMA; DISTINCT CLINICOPATHOLOGICAL ENTITY; PRIMARY CUTANEOUS LYMPHOMAS; TREATMENT-OF-CANCER; CLINICAL-FEATURES; PROLYMPHOCYTIC LEUKEMIA; PROGNOSTIC-SIGNIFICANCE; CLASSIFICATION PROJECT; ATAXIA-TELANGIECTASIA; DEPSIPEPTIDE FR901228;
D O I
10.1097/00001622-200309000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review. T-cell/natural killer (T/NK)-cell lymphomas represent a group of poor-risk lymphoproliferative disorders that have only recently been recognized as distinct clinicopathologic entities. The average outcome with currently available therapy is substantially inferior to that of aggressive B-cell lymphomas. Significant gaps remain in our knowledge of their origin, diagnosis, and clinical spectrum. This review outlines recent developments in the biology and molecular genetics of these disorders, current diagnostic challenges, and future avenues for therapy. Recent findings. Several cancer-prone transgenic mouse models that develop predominantly T/NK-cell lymphomas have been produced in the past 2 to 3 years. These models point to an important role for chronic cytokine stimulation and for disruption of genes involved in the control of chromatin remodeling and maintenance of genome integrity in the pathogenesis of T-cell lymphomas. The recognition of T/NK-cell lymphomas has been greatly facilitated by the broad acceptance of standard diagnostic criteria and by the increasing availability of assays for the analysis of T-cell receptor rearrangement and a more precise definition of functional T/NK-cell subsets. New drugs with potential for use in T/NK-cell lymphomas, including monoclonal antibodies, tyrosine kinase inhibitors, synthetic retinoids, immunoconjugates, and immunosuppressive molecules with novel mechanisms of action are in the early phase of clinical investigation. Summary. Much remains to be learned in the pathogenesis, clinical spectrum, and optimal therapy of T/NK-cell lymphomas. The availability of animal models of disease, new diagnostic tools, and targeted drugs with novel mechanisms of action should lead to rapid progress in this group of malignancies in the near future.
引用
收藏
页码:353 / 362
页数:10
相关论文
共 50 条
  • [1] Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline
    Fox, Christopher P.
    Ahearne, Matthew J.
    Pettengell, Ruth
    Dearden, Claire
    El-Sharkawi, Dima
    Kassam, Shireen
    Cook, Lucy
    Cwynarski, Kate
    Illidge, Tim
    Collins, Graham
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (03) : 507 - 522
  • [2] Cutaneous Lymphomas: An Update. Part 1: T-Cell and Natural Killer/T-Cell Lymphomas and Related Conditions
    Kempf, Werner
    Kazakov, Dmitry V.
    Kerl, Katrin
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2014, 36 (02) : 105 - 123
  • [3] Pathology and biology of peripheral T-cell lymphomas
    de Leval, Laurence
    Gaulard, Philippe
    HISTOPATHOLOGY, 2011, 58 (01) : 49 - 68
  • [4] T- and T/natural killer-cell lymphomas of the salivary gland: A clinicopathologic, immunohistochemical and molecular study of six cases
    Chan, JKC
    Tsang, WYW
    Hui, PK
    Ng, CS
    Sin, VC
    Khan, SM
    Siu, LLP
    HUMAN PATHOLOGY, 1997, 28 (02) : 238 - 245
  • [5] Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas
    Watanabe, Takashi
    Kinoshita, Tomohiro
    Itoh, Kuniaki
    Yoshimura, Kenichi
    Ogura, Michinori
    Kagami, Yoshitoyo
    Yamaguchi, Motoko
    Kurosawa, Mitsutoshi
    Tsukasaki, Kunihiro
    Kasai, Masaharu
    Tobinai, Kensei
    Kaba, Harumi
    Mukai, Kiyoshi
    Nakamura, Shigeo
    Ohshima, Koichi
    Hotta, Tomomitsu
    Shimoyama, Masanori
    LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 813 - 821
  • [6] Primary Pancreatic Natural Killer/T-Cell Lymphoma
    Chon, Hyung Ku
    Choi, Keum Ha
    Kim, Tae Hyeon
    PANCREAS, 2020, 49 (03) : E21 - E23
  • [7] NK/T-cell lymphomas in children
    Lai, Catherine
    Dunleavy, Kieron
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (01) : 33 - 41
  • [8] Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas
    Abouyabis, Abeer N.
    Shenoy, Pareen J.
    Lechowicz, Mary Jo
    Flowers, Christopher R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (01) : 31 - 40
  • [9] A rational approach to the therapy of cutaneous T-cell lymphomas
    Dummer, R
    Haffner, AC
    Hess, M
    Burg, G
    ONKOLOGIE, 1996, 19 (03): : 226 - 230
  • [10] Targeted molecular therapy in peripheral T-cell lymphomas
    Roncolato, Fernando
    Gazzola, Anna
    Zinzani, Pier Luigi
    Pileri, Stefano A.
    Piccaluga, Pier Paolo
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (05) : 551 - 562